ATLANTA, GA -- (MARKET WIRE) -- March 23, 2007 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will host a conference call and webcast to discuss key clinical findings from the ARISE Phase III trial of AGI-1067 on Tuesday, March 27, 2007, at 4:00 PM EDT.
